

### Claim Amendments

Claims 1 – 7 (canceled)

Claim 8 (original): An isolated hOAT polypeptide.

Claim 9 (original): The polypeptide of Claim 8 having the hOAT amino acid sequence of SEQ. ID. NO. 2.

Claims 10 – 14 (canceled)

Claim 15 (original): A method comprising providing a covalently modified form of a nucleotide phosphonate analogue and determining whether or not the analogue is transported by hOAT.

Claim 16 (original): The method of Claim 15 wherein the nucleotide phosphonate analogue is a derivative of PMEA, cidofovir or PMPA.

Claims 17 – 18 (canceled)

Claim 19 (original): A method comprising identifying a drug-drug interaction by contacting a candidate drug with hOAT polypeptide and at least a second drug whose effect on hOAT-mediated transport of the candidate drug is to be determined, and analyzing the effect of the second one or more drugs on hOAT-mediated transport of the candidate drug.

Restriction/Election Requirement

The Office has required restriction to one of the following inventions:

Group I; Claims 1-7 and 10, drawn to isolated nucleic acids classified in class 536 and 435, subclasses 23.5 and 320.1, respectively.

Group II; Claims 8 and 9, drawn to isolated polypeptides classified in class 530, subclass 350.

Group III; Claim 11 drawn to transgenic animals classified in class 800, subclass 13.

Group IV, Claim 12, 17 and 18, drawn to methods classified in class 435, subclass 6.

Group V, Claim 12, 17 and 18, drawn to methods classified in class 435, subclass 4.

Group VI, Claim 13, drawn to methods classified in class 435, subclass 7.1.

Group VII, Claim 14, drawn to methods classified in class 435, subclass 6.

#### Election

Applicants provisionally elect, without traverse, the invention of Group II, Claims 8 and 9. The single species of Claim 9 is provisionally elected for examination should the Office require such election in response to the election of Group II.